Neuropathy Treatment Risks: What Patients Should Know Before Starting Therapy

Neuropathy treatments vary widely; each carries specific risks. General categories:

1. Pharmacologic

• Gabapentinoids (gabapentin, pregabalin): Dizziness, sedation, edema, weight gain, misuse potential.
• SNRIs (duloxetine, venlafaxine): Nausea, insomnia, hypertension, sexual dysfunction, withdrawal syndrome.
• TCAs (amitriptyline, nortriptyline): Anticholinergic effects, orthostatic hypotension, QT prolongation, overdose lethality.
• Topicals (lidocaine, capsaicin): Local irritation, burning.
• Opioids: Avoid chronic use—addiction, OIH, constipation, falls.

2. Interventional

• Nerve blocks/epidurals: Infection, bleeding, nerve injury, dural puncture.
• Spinal cord stimulation: Lead migration, infection, hardware failure, revision surgery.
• Radiofrequency ablation: Neuritis, deafferentation pain.

3. Non-Invasive Neuromodulation

• TENS: Skin irritation, burns if misapplied.
• PEMF/rTMS: Seizure risk (rare), headache, discomfort; long-term safety data limited.
• Laser/light therapy: Eye injury if misdirected; evidence modest.

4. Complementary

• Acupuncture: Infection (if non-sterile), pneumothorax (rare), bruising.
• Supplements (alpha-lipoic acid, B12, acetyl-L-carnitine): Generally safe; interactions possible.

5. Rehabilitation

• PT/OT: Overuse injury if progression too aggressive.

Decision Framework

1. Accurate diagnosis (EMG/NCS, labs, imaging).
2. Start low-risk, evidence-based (lifestyle, topicals, gabapentinoids/SNRIs).
3. Escalate stepwise; reassess q4–8 weeks.
4. Multimodal approach usually superior to monotherapy.
5. Document goals, side effects, functional outcomes.

Shared decision-making with a neurologist/pain specialist optimizes safety and efficacy.